Association between pre-diagnostic circulating lipid metabolites and colorectal cancer risk: a nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC)
File(s)1-s2.0-S2352396424000598-main.pdf (1.75 MB)
Published version
Author(s)
Type
Journal Article
Abstract
BACKGROUND: Altered lipid metabolism is a hallmark of cancer development. However, the role of specific lipid metabolites in colorectal cancer development is uncertain. METHODS: In a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC), we examined associations between pre-diagnostic circulating concentrations of 97 lipid metabolites (acylcarnitines, glycerophospholipids and sphingolipids) and colorectal cancer risk. Circulating lipids were measured using targeted mass spectrometry in 1591 incident colorectal cancer cases (55% women) and 1591 matched controls. Multivariable conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations between concentrations of individual lipid metabolites and metabolite patterns with colorectal cancer risk. FINDINGS: Of the 97 assayed lipids, 24 were inversely associated (nominally p < 0.05) with colorectal cancer risk. Hydroxysphingomyelin (SM (OH)) C22:2 (ORper doubling 0.60, 95% CI 0.47-0.77) and acylakyl-phosphatidylcholine (PC ae) C34:3 (ORper doubling 0.71, 95% CI 0.59-0.87) remained associated after multiple comparisons correction. These associations were unaltered after excluding the first 5 years of follow-up after blood collection and were consistent according to sex, age at diagnosis, BMI, and colorectal subsite. Two lipid patterns, one including 26 phosphatidylcholines and all sphingolipids, and another 30 phosphatidylcholines, were weakly inversely associated with colorectal cancer. INTERPRETATION: Elevated pre-diagnostic circulating levels of SM (OH) C22:2 and PC ae C34:3 and lipid patterns including phosphatidylcholines and sphingolipids were associated with lower colorectal cancer risk. This study may provide insight into potential links between specific lipids and colorectal cancer development. Additional prospective studies are needed to validate the observed associations. FUNDING: World Cancer Research Fund (reference: 2013/1002); European Commission (FP7: BBMRI-LPC; reference: 313010).
Date Issued
2024-03
Date Acceptance
2024-02-05
Citation
EBioMedicine, 2024, 101
ISSN
2352-3964
Publisher
Elsevier
Journal / Book Title
EBioMedicine
Volume
101
Copyright Statement
© 2024 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND IGO license
(http://creativecommons.org/licenses/by-nc-nd/3.0/igo/).
(http://creativecommons.org/licenses/by-nc-nd/3.0/igo/).
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/38412638
Subjects
Case-Control Studies
Colorectal Neoplasms
Female
Humans
Male
Phosphatidylcholines
Prospective Studies
Risk Factors
Sphingolipids
Acylcarnitines
Colorectal cancer
Glycerophospholipids
Lipids
Metabolomics
Sphingolipids
Publication Status
Published
Coverage Spatial
Netherlands
Article Number
105024
Date Publish Online
2024-02-26